{"entity":{"id":"nct05651932","kind":"trial","name":"A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma","aka":[],"tldr":"A phase 1 trial of Gintemetostat run by K36 Therapeutics, Inc., now recruiting.","summary":"A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma is a phase 1 interventional study registered as NCT05651932 by K36 Therapeutics, Inc., with 165 participants planned, started 2023-02-22. Conditions recorded: Multiple Myeloma, Myeloma and Myeloma Multiple. Interventions recorded: Cohort A1 & A2: KTX-1001, Cohort B1 & B2: KTX-1001+Mezigdomide, Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®) and Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid).","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05651932","url":"https://clinicaltrials.gov/study/NCT05651932"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["gintemetostat"],"companies":["k36-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05651932","phase":"1","setting":"A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma","sponsor":"K36 Therapeutics, Inc.","enrolled":165,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05651932/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"gintemetostat","kind":"drug","name":"Gintemetostat","route":"/drugs/gintemetostat/"}],"company":[{"id":"k36-therapeutics","kind":"company","name":"K36 Therapeutics","route":"/companies/k36-therapeutics/"}]}}